Pharmaceutical Contract Manufacturing Market: By Type, OTC Medicines, Others, By Drug Type & By Region - Forecast 2016-2021

  • ID: 3973750
  • Report
  • 135 pages
  • IndustryARC
1 of 3
Global pharmaceutical manufacturing companies are facing extensive cost containment pressures, owing to global economic recession, and in addition increasing competition has compelled them to focus more on R&D, outsource manufacturing of drugs to contract manufacturers, and focus on their core business processes. Globally, development of latest and advance technology, rise in the demand for generic drugs, increasing government initiative across the globe, growing costing issues owing to global economic constraints, and increase in demand & supply gap of pharmaceutical products, due to rapidly rising population are the prime growth drivers of global pharmaceutical contract manufacturing market. In addition, increase in adoption of pharmaceutical contract manufacturing among pharmaceutical companies, owing to need for cost minimization, and emerging economies such as China, India and others, will create new opportunities for global pharmaceutical contract manufacturing market. However, increasing lead time & logistics costs, and issues in capacity utilization are the key restraints for global pharmaceutical contract manufacturing market.

Geographically North America dominated global pharmaceutical contract manufacturing market because of growing demand of generic drugs, increasing government initiative, and technological advancement. Asia Pacific is projected to have fastest growth, owing to rapidly increasing aging population leading to rise in gap between demand and supply of pharmaceutical products, availability of low cost skilled workforce, and favourable government policies, in developing nations such as China, and India in this region. Among all the type of contract manufacturing, Final Dosage Form (FDF) has the highest market share in global pharmaceutical contract manufacturing market. Solid dose formulation has the majority of share in global pharmaceutical contract manufacturing market, owing to its patient compliance, cost effectiveness, and easy availability.

This report identifies the global pharmaceutical contract manufacturing market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global pharmaceutical contract manufacturing market.

This report segments global pharmaceutical contract manufacturing market on the basis of type, drug type, and regional market as follows:
Pharmaceutical Contract Manufacturing Market, By Type: Advanced Drug Delivery Products, Active Pharmaceutical Ingredients (API), OTC Medicines, Nutritional products, Final Dosage Form (FDF), and Packaging Contract Manufacturing
The report has focused study on pharmaceutical contract manufacturing market by basis of drug type such as: Solid Dose Formulations, Liquid and Semi-Solid Dose Formulations, Injection Dose Formulations
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the pharmaceutical contract manufacturing market. Some of the major companies’ profiles in detail are as follows:
Catalent Pharma Solutions
Jubilant Life Sciences Limited
Royal DSM N.V.

HAUPT Pharma AG
Royal DSM N.V.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Pharmaceutical Contract Manufacturing Market – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis

4. Pharmaceutical Contract Manufacturing Market– Market Forces
4.1. Drivers
4.1.1. global economic constraints has led to increase in cost issues
4.1.2. Rising demand for generic drugs
4.2. Restraints
4.2.1. Increasing lead time & logistics costs
4.3. Opportunities
4.3.1. Emerging economies
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Pharmaceutical Contract Manufacturing Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Pharmaceutical Contract Manufacturing Market, By Type
6.1. Advanced Drug Delivery Products
6.2. Active Pharmaceutical Ingredients (API)
6.3. OTC Medicines
6.4. Nutritional products
6.5. Final Dosage Form (FDF)
6.6. Packaging Contract Manufacturing

7. Pharmaceutical Contract Manufacturing Market, By Drug Type
7.1. Solid Dose Formulations
7.2. Liquid and Semi-Solid Dose Formulations
7.3. Injection Dose Formulations

8. Pharmaceutical Contract Manufacturing Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Pharmaceutical Contract Manufacturing – Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
10.1. Catalent Pharma Solutions
10.2. Jubilant Life Sciences Limited
10.3. Royal DSM N.V.
10.4. HAUPT Pharma AG
10.5. Royal DSM N.V.
10.6. NextPharma
10.7. Althea Technologies
10.8. Nipro Corp
10.9. Abbott Laboratories
10.10. Kemwell Pvt. Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of Expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll